Quantum BioPharma is trading 5.2% down at $3.75, with no new company-specific announcement identified to explain the September 29 move. - FDA IND clearance for Lucid-MS and Phase 2 trial news had been reported before this session. - Broader sentiment may be a headwind as investors reacted to sharply weaker consumer confidence and fewer job openings, amid concerns about inflation, oil and bond yields. - Supplied index moves were below 0.5%, so the decline cannot be confidently attributed to the market alone.